Alkermes, Inc. (ALKS) Posts Wider than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts ALKS Hot Sheet
Price: $46.10 -1.66%
Revenue Growth %: +17.7%
Financial Fact:
Total revenues: 38.5M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +17.7%
Financial Fact:
Total revenues: 38.5M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alkermes, Inc. (NASDAQ: ALKS) reported Q1 loss of ($0.14), $0.02 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $61.9 million versus the consensus estimate of $52.67 million.
Alkermes reported pro forma EPS during the quarter of $0.02, excluding one-time items and share-based compensation expense, compared to a pro forma loss per share of ($0.09) last year.
Alkermes reported pro forma EPS during the quarter of $0.02, excluding one-time items and share-based compensation expense, compared to a pro forma loss per share of ($0.09) last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Reiterates Outperform Rating on Alkermes (ALKS)
- Victoria's Secret & Co. (VSXY) Tops Q2 EPS by 20c ; Offers Guidance
- John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
